8-K: Avidity Biosciences Appoints Deloitte & Touche as New Independent Auditor, Replacing BDO USA

Avidity Biosciences has replaced BDO USA with Deloitte & Touche LLP as its independent registered public accounting firm for the year ending December 31, 2025, effective after filing the Q1 Form 10-Q.

Summary

• Avidity Biosciences has appointed Deloitte & Touche LLP as its new independent registered public accounting firm for the year ending December 31, 2025.
• The appointment was approved by the Audit Committee on April 25, 2025, following a competitive process.
• Deloitte's appointment becomes effective immediately after the filing of the company's quarterly report on Form 10-Q for the quarter ended March 31, 2025.
• BDO USA, P.C. was dismissed as the company's independent registered public accounting firm on April 25, 2025, also effective upon the filing of the Q1 Form 10-Q.
• BDO's audit reports for the years ended December 31, 2024 and 2023 did not contain any adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
• There were no disagreements between Avidity and BDO on accounting principles, financial statement disclosure, or auditing scope or procedure during the company's two most recent fiscal years and through April 25, 2025.
• The company reported a material weakness in its internal control over financial reporting for the year ended December 31, 2023, which was remediated during fiscal year 2024.
• BDO issued an unqualified opinion on the effectiveness of the company's internal control over financial reporting as of December 31, 2024.

Sentiment

Score: 7

Explanation: The announcement is neutral to slightly positive. The change in auditors is not inherently negative, and the remediation of the material weakness in internal control is a positive development.

Positives

• The audit reports of BDO on the consolidated financial statements of the Company as of and for the years ended December 31, 2024 and 2023 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.
• During fiscal year 2024, the Company remediated such material weakness, and BDO issued an unqualified opinion on the effectiveness of the Company's internal control over financial reporting as of December 31, 2024.

Negatives

• The Company reported a material weakness in its internal control over financial reporting during the fiscal year ended December 31, 2023.

Risks

• The transition to a new auditor could present short-term challenges as Deloitte familiarizes itself with Avidity's financial systems and controls.
• Although the material weakness in internal control was remediated, any future lapses in internal controls could lead to adverse audit opinions or regulatory scrutiny.

Future Outlook

The company anticipates a smooth transition to Deloitte & Touche LLP as its independent registered public accounting firm and expects to maintain effective internal controls over financial reporting.

Industry Context

Switching auditors is a fairly common practice among publicly traded companies. Companies may switch auditors for a variety of reasons, including cost, expertise, or to obtain a fresh perspective on their financial statements. The selection of Deloitte, a Big Four accounting firm, suggests Avidity's commitment to maintaining high standards of financial reporting.

Comparison to Industry Standards

• The appointment of Deloitte & Touche LLP aligns Avidity Biosciences with industry standards, as Deloitte is one of the 'Big Four' accounting firms often engaged by publicly traded companies.
• Comparable companies in the biotechnology sector, such as Moderna or BioNTech, also utilize reputable auditing firms to ensure financial transparency and compliance.
• The remediation of the material weakness in internal control over financial reporting demonstrates Avidity's commitment to meeting regulatory requirements, similar to other companies addressing internal control deficiencies identified during audits.

Stakeholder Impact

• Shareholders can expect continued financial transparency and compliance with regulatory requirements.
• Employees in the finance and accounting departments will work with a new auditing firm.
• The change in auditors is unlikely to have a significant impact on customers, suppliers, or creditors.

Next Steps

• Filing of the Q1 Form 10-Q, after which Deloitte's appointment becomes effective.
• Deloitte to begin its audit of the company's financial statements for the year ending December 31, 2025.

Key Dates

Keywords

independent auditor, Deloitte & Touche, BDO USA, audit committee, financial reporting, internal control, Avidity Biosciences